Redefining BCLC B, Intermediate-Stage HCC: Is There a Role for Combination Systemic Therapy?
January 29th 2021BCLC B intermediate stage hepatocellular carcinoma, defined as patients with unresectable, liver-limited disease and preserved liver function, encompasses a broad range of patients with variable tumor size, number, and location.
Oncolytic Viral Therapy: A Unique Approach to Explore in GI Cancers
December 11, 2020 - Oncolytic viral therapy has been heavily investigated across oncology, but plenty of work still lies ahead to determine how this treatment approach can be applied in gastrointestinal malignancies.
FDA Approval Insights: Tazemetostat in Relapsed/Refractory Follicular Lymphoma
October 1st 2020In our exclusive interview, Dr. Leonard discusses the FDA approval of tazemetostat in patients with relapsed/refractory follicular lymphoma whose tumors are EZH2 positive, as well as those with relapsed/refractory follicular lymphoma who have no other available satisfactory treatment options, and the benefits of providing another agent for this subset of patients.
From the Ophthalmologist’s Eye: Managing Ocular Toxicities With Belantamab Mafodotin in Myeloma
September 25th 2020Shaily Shah, MD, discusses disease and treatment-related ocular toxicities that can arise in patients with cancer, specific management strategies for patients receiving belantamab mafodotin who develop ocular toxicities, and the importance of collaborative management of these patients.